Published 4 days ago • loading... • Updated 3 days ago

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

The Rosen Law Firm is seeking a lead plaintiff for a securities class action against ImmunityBio, Inc. involving alleged fraud during the Class Period from January 19 to March 24, 2026, with a May 26, 2026 deadline.
According to the lawsuit, defendant Patrick Soon-Shiong allegedly overstated Anktiva's capabilities, causing defendants' statements about ImmunityBio's business and prospects to be materially false and misleading throughout the Class Period.
Investors who purchased IBRX securities during the Class Period may qualify for compensation through a contingency fee arrangement, requiring no out-of-pocket costs or advance payment from class members.
A lead plaintiff acts as a representative party directing litigation on behalf of other class members, and those seeking this role must move the Court no later than May 26, 2026.
Founding partner Laurence Rosen leads The Rosen Law Firm, which specializes in securities class actions and previously secured over $438 million for investors in 2019 alone.

Insights by Ground AI